You are here

Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

3 Best Big Pharma Stocks for 2018

Motley Fool

Tue, 01/2/18 - 11:06 am

Tags:

JNJ, Celgene, AbbVie

Here's How AbbVie Inc. Crushed It in 2017

Yahoo/Motley Fool

Tue, 12/26/17 - 09:48 am

Tags:

AbbVie, biosimilars, Humira, Imbruvica

Another death mars AbbVie’s latest batch of promising data for its star rheumatoid arthritis drug

BioPharma Dive

Wed, 12/20/17 - 11:42 am

Tags:

AbbVie, rheumatoid arthritis, Upadacitinib, ABT-494

The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate

Endpoints

Sun, 12/17/17 - 11:47 am

ASH 2017: What you missed

BioPharma Dive

Wed, 12/13/17 - 06:35 pm

Tags:

ASH17, Biomarin, Spark Therapeutics, Gilead Sciences, Novartis, Juno Therapeutics, AbbVie, Roche, JNJ

AbbVie Makes Progress on Quest to Diversify

Motley Fool

Tue, 12/12/17 - 10:40 pm

Tags:

AbbVie, biosimilars, Roche, Venclexta

#ASH17: Verastem’s AbbVie castoff is headed for the FDA — even after missing overall survival goal

Endpoints

Sun, 12/10/17 - 11:22 pm

Tags:

ASH17, AbbVie, Verastem, FDA, duvelisib, chronic lymphocytic leukemia

NICE nods for AbbVie in hep C and Novartis in lung cancer

Pharma Times

Sun, 12/10/17 - 09:53 am

Tags:

NICE, AbbVie, hepatitis C, Maviret, Novartis, Zykadia, ALK-positive non-small cell lung cancer

In a crowded market, AbbVie may still have a best-in-class psoriasis prospect up its sleeve: analyst

Fierce Pharma

Wed, 12/6/17 - 09:53 am

Tags:

AbbVie, psoriasis, risankizumab, JNJ, Tremfya

AbbVie's stock climbs after positive late-stage trial results of psoriasis treatment

Marketwatch

Mon, 12/4/17 - 09:48 am

Tags:

AbbVie, psoriasis, risankizumab, clinical trials

5 Top Biotech Stocks

Motley Fool

Sun, 12/3/17 - 11:33 am

Tags:

biotech, AbbVie, Celgene, Gilead Sciences, Ligand Pharmaceuticals, Vertex Pharmaceuticals

#ASH17: Late breaker from AbbVie, Roche highlights a blockbuster breakout opportunity for Venclexta in CLL

Endpoints

Fri, 11/24/17 - 09:25 am

Tags:

ASH, AbbVie, Roche, Venclexta, CLL, chronic lymphocytic leukemia

Boehringer wins EU approval for Humira biosimilar

BioPharma Dive

Wed, 11/15/17 - 08:53 pm

Tags:

Boehringer Ingelheim, Europe, Humira, biosimilars, Cyltezo, AbbVie

7 Things AbbVie's Top Executives Just Said That You'll Want to Know

Motley Fool

Fri, 11/10/17 - 10:19 am

Tags:

AbbVie, Humira, Imbruvica, Venclexta, Amazon, tax reform

Could pain data give Lilly's baricitinib back its edge?

BioPharma Dive

Tue, 11/7/17 - 09:48 am

Tags:

Eli Lilly, baricitinib, Humira, AbbVie, rheumatoid arthritis

Humira back on top of TV spending list for October, ahead of Lyrica and Victoza

Fierce Pharma

Mon, 11/6/17 - 10:12 am

Tags:

Humira, Lyrica, Victoza, AbbVie, Pfizer, Novo Nordisk, television ads, DTC ads

AbbVie Overpromises on Humira

Bloomberg

Sat, 11/4/17 - 08:47 am

Tags:

There's a Lot to Like in AbbVie's Q3 Update

Motley Fool

Fri, 10/27/17 - 02:44 pm

Tags:

AbbVie, earnings, Humira, Imbruvica, Mavyret

AbbVie says Humira sales will balloon to $21 bln in 2020, shares rise

Yahoo/Reuters

Fri, 10/27/17 - 11:05 am

Tags:

AbbVie, Humira, earnings

AbbVie boasts a PhIII sweep for top psoriasis contender risankizumab, but it has lots of competition

Endpoints

Thu, 10/26/17 - 09:28 am

Tags:

AbbVie, psoriasis, risankizumab, Humira, Stelara, clinical trials

Pages

last 30 twitter posts